ACP-104
Drug200 mg, tablet, BID, 6 weeks
NCT Number: NCT00490516
This is a randomized, double-blind, placebo-controlled parallel-group, 6-week study, evaluating two dose levels of ACP-104 or Placebo twice a day in patients with schizophrenia who are experiencing an acute psychotic episode.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 2
Anaheim, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
In addition to the criteria described above, subjects will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of the subject's health, including psychosis (mental health -the extent to which subject is unable to think clearly), heart condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline condition does not meet all protocol-specified entry criteria).
200 mg, tablet, BID, 6 weeks
placebo, tablet BID, 6 weeks
Time frame: 6 weeks
ACADIA Pharmaceuticals Inc.
Industry
A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 in Acutely Psychotic Subjects With Schizophrenia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05808244
Mental Disorders, Psychosis
Kowloon, Hong Kong
View Trial DetailsNCT01945333
Mental Disorders, Psychotic Disorders
Brooklyn, New York, United States
View Trial DetailsNCT00001247
Mental Disorders, Psychotic Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT00001258
Basal Ganglia Diseases, Brain Diseases
Bethesda, Maryland, United States
View Trial Details